Nexalin Technology, Inc. (NXL)

Market Cap	1.29M -94.9%
Revenue (ttm)	217,155 +24.2%
Net Income	-8.99M
EPS	-13.92
Shares Out	829.40K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,450
Open	1.510
Previous Close	1.540
Day's Range	1.450 - 1.560
52-Week Range	1.410 - 43.500
Beta	4.34
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 17, 2026

About NXL

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 16, 2022
• Employees: 8
• Stock Exchange: Nasdaq
• Ticker Symbol: NXL
• Website: https://www.nexalin.com

Financial Performance

In 2025, Nexalin Technology's revenue was $301,647, an increase of 78.78% compared to the previous year's $168,721. Losses were -$8.22 million, 8.08% more than in 2024.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 5, 2026

Data Sources Report a data error